Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center
Journal of Clinical Medicine · 17.11.2024 · 13 (22) · 6926
DOI: 10.3390/jcm13226926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.11.2024. Verfasst von Mara Nike Blazon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Optometry, Medical University of Vienna, Waehringer Gürtel 18-20, 1090 Vienna, Austria. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Retinopathy of prematurity (ROP) remains a major cause of childhood blindness. Its pooled prevalence worldwide is 31.9%, and that of severe ROP is 7.5% among prematurely born babies. Investigating risk factors is essential for improving early detection and treatment outcomes.
Purpose
To determine the frequency and stages of ROP cases and evaluate the treatment methods for premature infants at the Medical University of Vienna.
Methods
In this retrospective study, 352 children who underwent ROP screening between 2018 and 2021 with a gestational age (GA) ≤ 32 weeks and/or a birth weight (BW) ≤ 1500 g were included.
Results
ROP was found in 144 (40.9%) of the 352 screened premature infants, with 17 (4.8%) requiring treatment. Significant risk factors included GA and BW, while sex and pregnancy type were not significant. The mean GA was 27.7 ± 2.5 weeks, and the mean BW was 989.1 ± 359.7 g. Infants with ROP had a lower GA (25.9 ± 1.7 weeks) and BW (778.6 ± 262.4 g) than those without ROP (28.9 ± 2.2 weeks; 1134.9 ± 345.9 g). GA and BW were significantly lower in infants developing ROP (p < 0.001). Stage 2 ROP was the most common severity in 74 children (51.4%). Laser therapy was the most common first-line treatment, used in 11 infants (64.7%), followed by anti-VEGF therapy, used in 6 infants (35.3%). Children were treated within 1.0 ± 0.6 days on average. Of the 17 infants treated, 14 (82.4%) showed initial regression. Three infants (17.6%) required re-treatment: two with initial anti-VEGF therapy and one after laser therapy.
Conclusions
The findings provide insights into ROP’s prevalence and treatment preferences at a university tertiary care center. GA and BW were confirmed to be significant predictors, aiding in early detection and informing treatment decisions. These insights will enable comparisons with similar studies and contribute to improved patient care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Optometry, Medical University of Vienna, Waehringer Gürtel 18-20, 1090 Vienna, Austria.
- Department of Pediatrics and Adolescent Medicine, Division of Neonatology, Intensive Care Medicine and Neuropediatrics, Comprehensive Center of Pediatrics, Medical University of Vienna, Waehringer Gürtel 18-20, 1090 Vie…
ORCID-Profile: Angelika Berger
Zitieren
APA
Blazon, M. N., Rezar-Dreindl, S., Wassermann, L., Neumayer, T., Berger, A., & Stifter, E. (2024). Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center. Journal of Clinical Medicine, 13(22), 6926. https://doi.org/10.3390/jcm13226926
Vancouver
Blazon MN, Rezar-Dreindl S, Wassermann L, Neumayer T, Berger A, Stifter E. Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center. Journal of Clinical Medicine. 2024;13(22):6926. doi:10.3390/jcm13226926
BibTeX
@article{Blazon2024,
author = {Blazon, Mara Nike and Rezar-Dreindl, Sandra and Wassermann, Lorenz and Neumayer, Thomas and Berger, Angelika and Stifter, Eva},
title = {Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {22},
pages = {6926},
doi = {10.3390/jcm13226926}
}
EUVIMED